Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New cancer drugs linked to fewer arrhythmias

Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Key clinical point: The novel targeted cancer therapies cause markedly fewer cardiac arrhythmias.

Major finding: Cancer patients treated with a tyrosine kinase inhibitor, immune checkpoint inhibitor, or another of the novel targeted therapies were 40% less likely than were those on anthracycline-based therapy to develop a treatment-induced cardiac arrhythmia up to 6 months after treatment initiation.

Study details: This was a retrospective single-center study including more than 5,000 cancer patients.

Disclosures: The presenter reported having no financial conflicts regarding his study, which was conducted free of commercial support.

Source: Nickel A et al. ACC 18, Abstract #900-06.

Read the article.

Citation:

Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

This Week's Must Reads

FDA postmarketing requirements, Nabhan C et al. JAMA Oncol. 2018 May 10. doi:10.1001/jamaoncol.2018.0610.

Upswing in childhood lymphomas, Siegel DA et al. ASPHO 2018, Abstract 605.

Dapagliflozin suppresses hepcidin, Ghanim HA et al. AACE 2018, Abstract 228.

Methotrexate or nelarabine plus chemo in pediatric T-ALL or T-L, Dunsmore KP et al. ASCO 2018, Abstract 10500.

Blood type is diarrhea destiny, Kumar P et al. J Clin Invest. 2018 May 17; doi: 10.1172/JCI97659.

Must Reads in Thrombosis

New cancer drugs linked to fewer arrhythmias, Nickel A et al. annual meeting of the American College of Cardiology ACC 18, Abstract #900-06.

Increase kidney function monitoring if INR exceeds 4.0, Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

2 approaches to diagnosing heparin-induced thrombocytopenia, Pishko A et al. Biennial summit of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018, Abstract 103

VTE prophylaxis unaddressed in acutely ill patients, Amin A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 51.

Warfarin users take 10 other drugs on average, Jacobson A et al. The biennial summit of the Thrombosis & Hemostasis Societies of North America 2018. Poster 2